[S29] The consideration of the ideal form of PMDA's review reports as drug information —from the perspectives of the regulatory authorities, medical institutions, and industries—

1:40 PM - 1:55 PM JST(4:40 AM - 4:55 AM UTC)

[S29-3] Utilization of PMDA review report in clinical practice and future expectations

○Susumu Wakabayashi^1,2 (1. Kyorin University Hospital, 2. Tokyo Healthcare University)

Password required to view

Enter the password to view the abstracts.
The password will be emailed to those who have completed the registration.